inflammation and glp-1 Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control GLP-1 Receptor Agonists Reduce Inflammation

In the present post hoc analysis published in Diabetes Care , Klein and colleagues examined data on the 16 996 adults participating in four large randomised, double-blind, placebo-controlled clinical trials assessing the safety and efficacy of GLP-1 RAs: the LEADER trial of liraglutide, the STEP 2 and SUSTAIN 6 trials of subcutaneous semaglutide, and the PIONEER 6 trial of oral semaglutide

Chi X, et al

V theo cc chuyn gia ca Dr Lacir, nu c th hp th tt th ch cn 1 liu trnh ca sn phm c hiu qu

Oral formulations must be taken on an empty stomach, absorbed differently, and may produce different side effect profiles despite delivering the same active compound

Figure 5: A) Time spent below range, time in range, time above high range, and time in tight range